CoreCap Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

CoreCap Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.4K	Sell	11,820 -1,000	-8%	-$3.33K	﹤0.01%	1470
2026 Q1	$39.4K	Buy	12,820 +234	+2%	+$904	﹤0.01%	1407
2025 Q4	$51.5K	Buy	12,586 +766	+6%	+$3.79K	﹤0.01%	1323
2025 Q3	$57.7K	Hold	11,820	–	–	﹤0.01%	1256
2025 Q2	$59.8K	Buy	+11,820	New	+$58.1K	﹤0.01%	1173
2024 Q2	–	Sell	-26	Closed	-$259	–	2386
2024 Q1	$259	Buy	+26	New	+$290	﹤0.01%	2391

Other funds holding RXRX

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

AWM

Accel Wealth Management Waverly, Iowa $444M AUM 31.14% 1-Year Est. Return

NWMG

National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return

WPC

Wedmont Private Capital West Chester, Pennsylvania $3.65B AUM 26.64% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

ICP

Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return

CoreCap Advisors's RXRX Position: Q2 2026 in Review

CoreCap Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 7.8% in Q2 2026, selling an estimated $3.33K and leaving 11,820 shares worth $43.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1470.

CoreCap Advisors first reported a position in RXRX in Q1 2024 and has held it in 6 quarters since. The position peaked at $59.8K in Q2 2025. 28 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

CoreCap Advisors held 11,820 shares of Recursion Pharmaceuticals worth $43.4K as of Q2 2026.
CoreCap Advisors sold 1,000 Recursion Pharmaceuticals shares in Q2 2026, an estimated $3.33K.
Recursion Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #1470 holding.
CoreCap Advisors first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
CoreCap Advisors's Recursion Pharmaceuticals position peaked at $59.8K in Q2 2025.
28 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.